Internal Medicine | Page 57 of 487 | Links Medicus Content Curation & Alerts in Medicine

RCT | Colistin monotherapy vs. combination therapy for carbapenem-resistant organisms

13 Jan, 2023 | 13:36h | UTC

Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms – NEJM Evidence

Commentary: Colistin Alone or with Meropenem: Is More Better? – NEJM Journal Watch

Retrospective Study | Clinical features and management of individuals admitted to hospital with monkeypox

13 Jan, 2023 | 13:33h | UTC

Clinical features and management of individuals admitted to hospital with monkeypox and associated complications across the UK: a retrospective cohort study – The Lancet Infectious Diseases

Peritoneal dialysis prescription and adequacy in clinical practice: Core Curriculum 2023

13 Jan, 2023 | 13:31h | UTC

Peritoneal Dialysis Prescription and Adequacy in Clinical Practice: Core Curriculum 2023 – American Journal of Kidney Diseases

Commentary on Twitter

Core Curriculum by @bourneauguste and @JoanneBargman:

Peritoneal Dialysis Prescription and Adequacy in Clinical Practice:https://t.co/myanGLKzIr (FREE) pic.twitter.com/DWbPrZrnM6

— AJKD (@AJKDonline) October 7, 2022

Report | Obstacles and opportunities in managing coexisting obesity and CKD

13 Jan, 2023 | 13:30h | UTC

Obstacles and Opportunities in Managing Coexisting Obesity and CKD: Report of a Scientific Workshop Cosponsored by the National Kidney Foundation and The Obesity Society – American Journal of Kidney Diseases

Study suggests delivering high concentrations of antibiotics into the implantation site is feasible for infections in implanted CV electronic devices

13 Jan, 2023 | 13:26h | UTC

Regional Antibiotic Delivery for Implanted Cardiovascular Electronic Device Infections – Journal of the American College of Cardiology (link to abstract – $ for full-text)

Commentaries:

Direct Delivery of Antibiotics to CV Device Pocket Infections Appears Promising – TCTMD

Regional Antibiotics for Implanted Cardiovascular Electronic Device Infections – American College of Cardiology

Cohort Study | Antibiotic exposure linked to increased risk of inflammatory bowel disease

13 Jan, 2023 | 13:25h | UTC

Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study – Gut

News Release: Frequent use of antibiotics may heighten inflammatory bowel disease risk in over 40s – BMJ Newsroom

Commentaries:

Antibiotics may increase risk of inflammatory bowel disease, study finds – CIDRAP

Antibiotic Exposure Positively Linked to IBD Development – HealthDay

Commentary on Twitter

#GUTPressRelease on the paper by @AdamFayeMD, @KristineAllin, @manasiagrawalmd, @PREDICTIBD et al

"Antibiotic use as a risk factor for inflammatory bowel disease across the ages: a population-based cohort study" viahttps://t.co/zc9bG3CpSm #GUTInTheNews pic.twitter.com/xra8wfEgnr

— Gut Journal (@Gut_BMJ) January 9, 2023

SR | Protein restriction for diabetic kidney disease

13 Jan, 2023 | 13:21h | UTC

Protein restriction for diabetic kidney disease – Cochrane Library

Summary: Low protein diets for adults with diabetic kidney disease – Cochrane Library

RCT | A 24-week, all-oral regimen for rifampin-resistant tuberculosis

12 Jan, 2023 | 13:27h | UTC

A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis – New England Journal of Medicine

Commentary: Trial results show superiority of shorter, all-oral treatment for drug-resistant TB – CIDRAP

Review | The pathogenesis and therapeutic strategies of heat stroke-induced liver injury

13 Jan, 2023 | 13:07h | UTC

The pathogenesis and therapeutic strategies of heat stroke-induced liver injury – Critical Care

WHO consolidated guidelines on tuberculosis | Drug-resistant tuberculosis treatment, 2022 update

12 Jan, 2023 | 13:30h | UTC

WHO consolidated guidelines on tuberculosis. Module 4: treatment – drug-resistant tuberculosis treatment, 2022 update – World Health Organization

RCT | Early treatment with Molnupiravir did not reduce hospitalizations in high-risk adults with COVID-19

12 Jan, 2023 | 13:24h | UTC

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial – The Lancet

Commentaries:

Molnupiravir does not reduce COVID-19 hospitalisations or deaths in vaccinated, high risk people – National Institute for Health and Care Research

Molnupiravir doesn’t cut Omicron hospitalization, death but can speed recovery – CIDRAP

An evidence and consensus-based definition of “Second Victim”

12 Jan, 2023 | 13:21h | UTC

An Evidence and Consensus-Based Definition of Second Victim: A Strategic Topic in Healthcare Quality, Patient Safety, Person-Centeredness and Human Resource Management – International Journal of Environmental Research and Public Health

RCT | Second-line levofloxacin-based quadruple therapy vs. bismuth-based quadruple therapy for Helicobacter pylori eradication

12 Jan, 2023 | 13:06h | UTC

Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial – The Lancet Gastroenterology & Hepatology (link to abstract – $ for full-text)

Commentary on Twitter

New research – Liou et al – Second-line levofloxacin-based quadruple therapy vs bismuth-based quadruple therapy for H pylori eradication and long-term changes to the gut #microbiota and antibiotic resistome: an RCThttps://t.co/Aipu3TRyFr #Hpylori #microbiome #AMR @emadelomar pic.twitter.com/aeFMAI3FCj

— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) December 20, 2022